Albireo Pharma is a clinical-stage company focused through its operating subsidiary on the development of therapies for orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is an ileal bile acid transporter (IBAT) inhibitor in development for pediatric cholestatic liver diseases, initially progressive familial intrahepatic cholestasis (PFIC). Albireo Pharma is headquartered in Boston, Massachusetts and its operating subsidiary is located in Gothenburg, Sweden.

Copyright West LLC. Minimum 15 minutes delayed.

Events & Presentations

2019 Annual Meeting

Albireo Corporate Overview